PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of PXD101 and bortezomib in
treating patients with advanced solid tumors or lymphomas. PXD101 and bortezomib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. PXD101 may
also cause cancer cells to look more like normal cells, and to grow and spread more slowly.
Giving PXD101 together with bortezomib may kill more cancer cells.